
==== Front
World J Clin Cases
WJCC
World Journal of Clinical Cases
2307-8960
Baishideng Publishing Group Inc

jWJCC.v12.i25.pg5739
10.12998/wjcc.v12.i25.5739
93248
Meta-Analysis
Prognostic significance of oligodendrocyte transcription factor 2 expression in glioma patients: A systematic review and meta-analysis
Li PC et al. Prognostic significance of Olig2 in glioma
Li Peng-Cheng Department of Neurosurgery, The Affiliated Nanchong Central Hospital of North Sichuan Medical College, Nanchong 637000, Sichuan Province, China

Yun De-Bo Department of Neurosurgery, The Affiliated Nanchong Central Hospital of North Sichuan Medical College, Nanchong 637000, Sichuan Province, China

Huang Ya-Xin Department of Transfusion, The Affiliated Nanchong Central Hospital of North Sichuan Medical College, Nanchong 637000, Sichuan Province, China

Huang Qian-Yi Department of Transfusion, The Affiliated Nanchong Central Hospital of North Sichuan Medical College, Nanchong 637000, Sichuan Province, China. huangqianyi2019@163.com

Author contributions: Li PC and Huang QY designed the research study; Li PC, Yun DB and Huang QY performed the research; Yun DB and Huang QY contributed analytic tools; Li PC, Huang QY and Huang YX analyzed the data and wrote the manuscript; All authors have read and approved the final manuscript.

Corresponding author: Qian-Yi Huang, MAMS, Master’s Student, Staff Physician, Department of Transfusion, The Affiliated Nanchong Central Hospital of North Sichuan Medical College, No. 97 South Renmin Road, Shunqing District, Nanchong 637000, Sichuan Province, China. huangqianyi2019@163.com

6 9 2024
6 9 2024
12 25 57395748
22 2 2024
27 5 2024
24 6 2024
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
2024
https://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
BACKGROUND

Gliomas are the most common primary central nervous system neoplasm. Despite recent advances in the diagnosis and treatment of gliomas, patient prognosis remains dismal. Therefore, it is imperative to identify novel diagnostic biomarkers and therapeutic targets of glioma to effectively improve treatment outcomes.

AIM

To investigate the association between oligodendrocyte transcription factor 2 (Olig2) expression and the outcomes of glioma patients.

METHODS

The PubMed, Embase, Cochrane Library, and China National Knowledge Infrastructure databases were searched for studies (published up to October 2023) that investigated the relationship between Olig2 expression and prognosis of glioma patients. The quality of the studies was assessed using the Newcastle Ottawa Scale. Data analyses were performed using Stata Version 12.0 software.

RESULTS

A total of 1205 glioma patients from six studies were included in the meta-analysis. High Olig2 expression was associated with better outcomes in glioma patients [hazard ratio (HR): 0.81; 95% (confidence interval) CI: 0.51-1.27; P = 0.000]. Furthermore, the results of subgroup meta-analysis showed that high expression of Olig2 was associated with poor overall survival in European patients (HR: 1.34; 95%CI: 0.79-2.27) and better prognosis in Asian patients (HR: 0.43; 95%CI: 0.22-0.84). The sensitivity analysis showed that no single study had a significant effect on pooled HR, and there was also no indication of publication bias according to the Egger’s and Begger’s P value test or funnel plot test.

CONCLUSION

High Olig2 expression may have a positive impact on the prognosis of glioma patients, and should be investigated further as a prognostic biomarker and therapeutic target for glioma.

Glioma
Oligodendrocyte transcription factor 2
Prognosis
Biomarker
Meta-analysis
==== Body
pmc Core Tip: The overall prognostic value of oligodendrocyte transcription factor 2 (Olig2) for glioma remains unclear. We performed the first meta-analysis of previously published studies related to the potential prognostic value of Olig2 in glioma patients to evaluate the association between Olig2 expression and the outcomes of glioma patients. Our findings suggest that high Olig2 expression may have a positive impact on the prognosis of glioma patients, and should be investigated further as a prognostic biomarker and therapeutic target for glioma.

INTRODUCTION

Gliomas are primary tumors of the central nervous system (CNS) that originate from glial cells. Despite advances in the diagnosis and treatment of gliomas, patient prognosis remains dismal, and the general survival duration of the patients is 12-14 months[1,2]. Therefore, it is critical to identify reliable biomarkers for glioma in order to predict patient prognosis, improve clinical outcomes, and devise suitable individualized treatment plans[3]. In recent years, the identification of early diagnostic molecular biomarkers has played a vital role in predicting overall survival and guiding personalized treatments for patients with glioma[4]. Oligodendrocyte transcription factor 2 (Olig2) in particular is significantly associated with mortality[5,6].

Olig2 is a basic helix-loop-helix neural transcription factor that is ubiquitously expressed in diffuse glioma cells with oligodendroglial and astrocytic morphologies and plays an important role in the development of gliomas[7-9]. It is also a specific marker of glioblastoma (GBM) progenitor-like cells with stem-cell properties that initiate gliomagenesis and reside in the subventricular zone[6,10]. Inhibition of the Olig2 pathway delays glioma growth and sensitizes tumor cells to radiation therapy[11]. Hence, Olig2 expression or activity is a promising therapeutic target for the discovery of novel candidate drugs against glioma[12].

In recent years, numerous studies have analyzed the relationship between Olig2 expression and prognosis in glioma patients. However, findings of a single study were often difficult to generalize due to differences in research methods, sample sizes, and populations. Therefore, the overall prognostic value of Olig2 for glioma remains unclear. Here, a meta-analysis systematically assessed the literature on the relationship between Olig2 expression and prognosis in glioma patients. To our knowledge, this is the first meta-analysis to evaluate the prognostic value of Olig2 in patients with glioma.

MATERIALS AND METHODS

Literature search

The articles were searched from the PubMed, Cochrane Library, Embase, and China National Knowledge Infrastructure databases using the following keywords and text words: (“glioma” or “glioblastoma” or “CNS cancer” or “glial cell tumor” or “GMB”) and (“oligodendrocyte transcription factor 2” or “Olig2”) and (“survival” or “mortality” or “prognosis” or “follow-up studies” or “incidence” or “clinical significance”). The final search was updated in October 2023. Furthermore, the reference lists of the selected research articles and reviews were manually searched for additional relevant publications.

Study selection

The inclusion criteria for the studies were as follows: (1) Diagnosed with glioma on the basis of pathological examination, and classified according to the World Health Organization (WHO) guidelines; (2) Investigated the prognostic relevance of Olig2 in glioma; and (3) Provided direct estimation of hazard ratio (HR) and included 95% (confidence interval) CI, or presented Kaplan-Meier curves. If the same glioma patient population was analyzed in more than one study, then the report with the largest sample size was kept.

The exclusion criteria were as follows: (1) Repetitious study; (2) Studies with sample size less than 30; (3) Letters, case reports, comments, meeting records, and reviews; (4) Animal or laboratory studies or other types of CNS malignancies studies; and (5) Studies lacking sufficient data and contact information of the authors.

Data extraction

Two independent reviewers (Li PC and Huang QY) independently extracted the data from the selected studies. In case of any discrepancies, the final decision was made by consulting with the third author (Yun DB). The following data were extracted: First author, year of publication, country, sample size, proportion of male patients, median age, WHO grade, technique used to assay Olig2 levels, cut-off level, follow-up time, and Newcastle Ottawa Scale (NOS) scores. The HR for Olig2 expression and the corresponding 95%CI for the Olig2low/negative (control) and Olig2high/positive (experimental) groups were directly extracted or obtained from the Kaplan-Meier curves. In case both univariate and multivariate analyses had been performed for the overall survival (OS), the multivariate analysis was preferentially extracted. If HR were not mentioned, the logarithm-transformed HR and variance were estimated on the basis of Kaplan-Meier curves using Engauge Digitizer version 12.1[13].

Risk of bias

Two reviewers (Li PC and Huang QY) independently assessed the quality of the primary studies using the NOS, with the full score of 9. Studies with NOS scores ≥ 6 were defined as high-quality. Any disagreements were resolved by joint discussion.

Statistical analysis

Stata Version 12.0 (Stata Corporation, College Station, TX, United States) was used for all statistical analyses. OS was compared on the basis of HR and 95%CI. HR greater than 1 indicated poor prognosis for patients with high/positive Olig2 expression. The heterogeneity of the studies was evaluated using the I2 metric. I2 > 50% indicated significant heterogeneity, and the analysis was performed using a random-effect model. I2 < 50% was indicative of non-significant heterogeneity, and the fixed-effect model was used[14]. Subgroup analyses were performed to investigate the potential causes of heterogeneity according to the country, sample size, median age, WHO grade, detection method of Olig2 expression, source, cut-off level, and follow-up time. P < 0.05 was considered statistically significant.

Sensitivity analysis was performed to evaluate the stability and reliability of the pooled effect size. if the results after exclusion were significantly different compared to the original, the sensitivity was high and the stability of the results was low. In contrast, the sensitivity was low and the results were considered stable and reliable. The publication bias was qualitatively tested by funnel plots and quantified by Begg’s and Egger’s tests.

RESULTS

Study selection

The process for literature retrieval and the results are summarized in Figure 1. A total of 162 potentially relevant articles were initially selected, of which 110 articles were excluded on the basis of the title and abstract: 11 studies were duplicates, 8 were reviews, 54 concerned a carcinoma not related to gliomas or GBM, and non-related to Olig2 (n = 37). The remaining 52 articles were further examined, and 46 irrelevant studies were excluded, including 30 without data, 6 incomplete data, 8 involving non-human subjects, and 2 reviews. Six articles were finally included in this meta-analysis, including three from Europe[15-17], and three from Asia[18-20].

Figure 1 Flow diagram of the literature search and study selection protocols.

Characteristics of studies and quality assessment

The general characteristics of the included studies are summarized in Table 1. The studies were published from 2016 to 2023, and three studies were conducted in Europe and three in Asia. A total of 1205 patients were included in these studies, and their age ranged from 49.95 years to 64 years. The minimum sample size was 73, and the maximum sample size was 471. Two studies evaluated grade II-IV gliomas and four examined grade IV glioma. The HR and 95%CI for OS could be directly extracted from two studies; it was calculated from the Kaplan-Meier curves in the remaining studies. In all studies, the Olig2 expression in the tumor tissues had been evaluated by immunohistochemistry (IHC). The percentage of patients with Olig2-positive gliomas ranged from 18.42% to 95.75%. The follow-up time ranged from 30 months to 60 months. All included studies were high-quality with NOS scores ≥ 6.

Table 1 Characteristics of included studies

Ref.	Year	Country	Male/All sex	Positive males	Positive females	Median age	Grade I+II/III+IV	Positive I+II/III+IV	Method	HR and 95%CI	HR and 95%CI source	Cut-off	Follow-up time in months	NOS score	
Batista et al[15]	2016	Spain	79/152	13	58	-	0+77/75+0	0+12/16+0	IHC	0.98 (0.84-1.15)	Reported	-	50	7	
Schäfer et al[16]	2018	Germany	282/471	268	183	50.6	0+111/141+219	0+106/137+208	IHC	2.37 (1.37-4.01)	Reported	10	-	6	
Behling et al[17]	2020	Germany	67/113	-	-	64	0/0+113	0/0+89	IHC	1.16 (0.66-2.03)	K-M curve	10	37	7	
Zhong et al[18]	2020	China	167/277	60	60	51	0/0+277	0/0+216	IHC	0.66 (0.46-0.94)	K-M curve	10	60	6	
Zhou et al[19]	2023	China	49/73	29	13	49.95	0/0+73	0/0+42	IHC	0.11 (0.05-0.65)	K-M curve	30	30	6	
Mei et al[20]	2023	China	78/119	-	-	51.1	0/0+119	0/0+74	IHC	0.49 (0.28-0.82)	K-M curve	10	60	7	
HR: Hazard ratio; IHC: Immunohistochemistry; K-M: Kaplan-Meier; NOS: Newcastle Ottawa Score.

Correlation between OS and Olig2 expression in gliomas

The pooled HR was 0.81 (95%CI: 0.51-1.27, P = 0.000), suggesting that high Olig2 expression is a protective factor in glioma patients. Figure 2 shows a forest plot of the association between Olig2 expression and OS. Due to the significant heterogeneity among the studies (Cochran’s Q, I2 = 84.5%, P = 0.000), we used a random model for the meta-analysis.

Figure 2 Forest plot illustrating the relationship between oligodendrocyte transcription factor 2 expression and overall survival in glioma patients. Each study is accompanied by a point estimate of its hazard ratio (HR) and 95% confidence interval (CI) (extending lines). The diamonds represent the estimated pooled effect (labelled ‘total’).

Sub-group analysis

For heterogeneity values > 50%, meta-regression and subgroup analysis were performed to explore its potential source, and the results are summarized in Table 2. We stratified the patients based on the geographical area, sample size, median age, WHO grade, data extraction method, cut-off level, and follow up period. The results of subgroup analysis indicate that the geographical area may be related to heterogeneity. As shown in Figure 3, high expression of Olig2 was associated with better OS in patients of Asian descent (HR = 0.43, 95%CI: 0.22-0.84, P = 0.027) and with poor OS in European patients (HR = 1.34, 95%CI: 0.79-2.27, P = 0.008). No significant difference was observed among the other subgroups.

Figure 3 Forest plot for the association between oligodendrocyte transcription factor 2 expression and overall survival in terms of subgroup analysis of the testing index. HR: Hazard ratio.

Table 2 Subgroup analysis of the relationships between oligodendrocyte transcription factor 2 expression and overall survival

Comparison variables	Number of studies	Number of people	HR and 95%CI	P value	Heterogeneity by I2 statistics	
Total	6	1205	0.81 (0.51-1.27)	0.000	84.5	
Country						
Europe	3	736	1.34 (0.79-2.27)	0.008	79.3	
Asian	3	469	0.43 (0.22-0.84)	0.027	72.3	
number						
> 150	3	900	1.10 (0.65-1.86)	0.001	86.7	
≤ 50	3	305	0.46 (0.17-1.29)	0.002	84.0	
Median age
						
> 50
	4
	980
	0.96 (0.50-1.84)
	0.000
	85.8
	
≤ 50	1	73	0.11 (0.03-0.40)	-	-	
No referred	1	152	0.98 (0.84-1.15)	-	-	
WHO grade						
II-III	2	404	1.47 (0.62-3.47)	0.002	89.6	
IV	4	801	0.72 (0.36-1.45)	0.000	87.0	
Method						
Reported	2	623	1.47 (0.62-3.47)	0.002	89.6	
K-M curve	4	582	0.56 (0.31-1.01)	0.006	76.0	
Cut-off						
> 10	1	73	0.11 (0.03-0.40)	0.000	85.8	
≤ 10	4	980	0.96 (0.50-1.84)	-	-	
Follow up time	
	
	
	
	
	
> 50	2	396	0.60 (0.45-0.81)	0.366	0.0	
≤ 50	3	338	0.67 (0.31-1.46)	0.003	82.6	
HR: Hazard ratio; K-M: Kaplan-Meier; WHO: World Health Organization.

Sensitivity analysis and publication bias

The sensitivity analysis results showed that they are reliable (Figure 4). The funnel chart did not show any signs of publication bias, and Begger’s test was applied to provide statistical evidence for funnel plot symmetry. As expected, the P value of Begger’s test was 0.260 (Figure 5) and the P value of Egger’s test was 0.532 (Figure 6). Thereby, the possibility of publication bias can be ruled out in this study.

Figure 4 Sensitivity analysis of the relationship between oligodendrocyte transcription factor 2 and overall survival.

Figure 5 Begger’s funnel plot for the publication bias test of the oligodendrocyte transcription factor 2 expression and overall survival of gliomas.

Figure 6 Egger’s funnel plot for the publication bias test of the oligodendrocyte transcription factor 2 expression and overall survival of gliomas.

DISCUSSION

The considerable biological and genetic heterogeneity among glioma cells may account for the poor overall survival of glioma patients[21]. Therefore, it is imperative to identify novel diagnostic biomarkers and therapeutic targets of glioma to effectively improve treatment outcomes[22]. The interaction between inflammatory factors and tumor cells and other components of the tumor microenvironment may influence prognosis[23-25]. For example, Rahbar et al[26] found that higher numbers of neutrophils and macrophages in and around glioma tumors correlated with a shorter time to tumor progression. This overall poor prognosis may in some part be attributed to the immunosuppressive mediators within the tumor environment. However, the changes of these serological markers are not restricted to specific tumors and may be indicative of cancer growth in general. The current research focus for gliomas is the identification of novel targeted molecular markers. Previous studies have shown that Olig2 is a CNS-restricted transcription factor that is overexpressed in all grades of diffuse gliomas and plays a critical role in glial progenitor proliferation[27]. Trépant et al[6] identified Olig2 as the most specific GBM stem cell marker. In addition, several integrative studies have demonstrated that Olig2 directly activates regulators of cell cycle and oncogenic factors in tumors, and accelerates proliferation during tumorigenesis. In fact, deletion of Olig2 has been shown to delay glioma growth and improve survival[28-30]. However, some research groups have reported that higher Olig2 expression correlates with better overall survival of glioma patients[31-34].

To further ascertain the prognostic role of Olig2, we performed a systematic meta-analysis. Six eligible studies with 1205 patients were included, and the pooled HR with 95%CI were calculated. The final results showed that Olig2high/positive expression was associated with better outcomes in glioma patients (HR = 0.81). We did not find any evidence of publication bias among the included studies. Based on these results, we can conclude that our results are reliable, and high expression of Olig2 has a predictive value for glioma patients.

Interestingly, the results of meta-regression analysis indicate that high expression of Olig2 had opposite effects on the OS of European and Asian patients (age, WHO grade, etc may not be potential sources of heterogeneity). Olig2 was an indicator of favorable prognosis in the Asian cohorts (P < 0.05), and a similar trend was observed with the survival data retrieved from the Cancer Genome Atlas database. However, European glioma patients with lower Olig2 expression (10% cut-off) survived longer compared to the Olig2high patients (P = 0.008). These findings might be attributed to the heterogeneous clinical outcomes of glioma due to other prognostic markers or the complex tumor micro-environment, which should be assessed in future research. The present study was performed on a heterogeneous population of glioma patients, all of whom underwent resection, subtotal resection or biopsy followed by the same adjuvant therapy (chemotherapy and radiotherapy). The extent of tumor resection is an established prognostic factor for glioma[35]. However, surgical habits may vary across the different regions of Europe and Asia. In addition, previous studies have shown that Olig2 is not significantly expressed in glioma type II and III[36,37]. However, all WHO graded II-III glioma cases in the studies included in this meta-analysis were from Europe. This may be one of the reasons that affected the results of our subgroup analysis.

However, this study has several limitations that ought to be considered. Despite our efforts to collect all relevant data, the number of cases was too few, resulting in potential publication bias. Furthermore, some studies did not provide complete results and data, which may reduce the reliability of Olig2 expression as a prognostic indicator of glioma. In all included studies, Olig2 expression was detected by IHC. However, the results of IHC were affected by the primary antibody clones and concentrations. We were unable to perform a subgroup analysis of different antibodies to evaluate the underlying bias of the detection method on the pooled HR. In addition, all six studies were single center retrospective analyses with different cut-off values, which can also lead to bias. Furthermore, the HR with 95%CI for some studies were obtained from the Kaplan-Meier curve and not directly extracted, which may have increased the potential for bias. The articles included in this meta-analysis were also limited to those published in English and Chinese, resulting in publication bias due to the possible exclusion of relevant studies in other languages. In addition, differences in the polyclonal anti-Olig2 antibody testing kits and tumor sample preparation, and possible experimental errors may have introduced information bias, thereby affecting the measurement of Olig2 levels. It is important to note that we focused on the expression and not the activity of Olig2, which may or may not be correlated to each other. Thus, every factor that may have affected the analysis should be fully considered. In addition, multi-center cohort studies with larger sample sizes are needed to validate our findings, along with a deeper exploration of the functional mechanisms.

CONCLUSION

High Olig2 expression may have a positive impact on the prognosis of glioma patients, and Olig2 is a potential biomarker and therapeutic target that warrants further investigation. In light of the limitations of the current analysis, well-designed prospective clinical studies are required to elucidate the role of Olig2 in glioma progression to further evaluate its predictive value for glioma patients.

Conflict-of-interest statement: The authors deny any conflict of interest.

PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Medicine, research and experimental

Country of origin: China

Peer-review report’s classification

Scientific Quality: Grade B, Grade B

Novelty: Grade A, Grade B

Creativity or Innovation: Grade B, Grade B

Scientific Significance: Grade B, Grade C

P-Reviewer: Hashimoto K S-Editor: Luo ML L-Editor: Filipodia P-Editor: Yuan YY
==== Refs
1 Goodenberger ML Jenkins RB Genetics of adult glioma Cancer Genet 2012 205 613 621 23238284
2 Louis DN Perry A Reifenberger G von Deimling A Figarella-Branger D Cavenee WK Ohgaki H Wiestler OD Kleihues P Ellison DW The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary Acta Neuropathol 2016 131 803 820 27157931
3 Huse JT Aldape KD The evolving role of molecular markers in the diagnosis and management of diffuse glioma Clin Cancer Res 2014 20 5601 5611 25398843
4 Olar A Aldape KD Using the molecular classification of glioblastoma to inform personalized treatment J Pathol 2014 232 165 177 24114756
5 Bouchart C Trépant AL Hein M Van Gestel D Demetter P Prognostic impact of glioblastoma stem cell markers OLIG2 and CCND2 Cancer Med 2020 9 1069 1078 31568682
6 Trépant AL Bouchart C Rorive S Sauvage S Decaestecker C Demetter P Salmon I Identification of OLIG2 as the most specific glioblastoma stem cell marker starting from comparative analysis of data from similar DNA chip microarray platforms Tumour Biol 2015 36 1943 1953 25384509
7 Ligon KL Alberta JA Kho AT Weiss J Kwaan MR Nutt CL Louis DN Stiles CD Rowitch DH The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas J Neuropathol Exp Neurol 2004 63 499 509 15198128
8 Lu QR Park JK Noll E Chan JA Alberta J Yuk D Alzamora MG Louis DN Stiles CD Rowitch DH Black PM Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors Proc Natl Acad Sci USA 2001 98 10851 10856 11526205
9 Bouvier C Bartoli C Aguirre-Cruz L Virard I Colin C Fernandez C Gouvernet J Figarella-Branger D Shared oligodendrocyte lineage gene expression in gliomas and oligodendrocyte progenitor cells J Neurosurg 2003 99 344 350 12924709
10 Wang Y Yang J Zheng H Tomasek GJ Zhang P McKeever PE Lee EY Zhu Y Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model Cancer Cell 2009 15 514 526 19477430
11 Mehta S Huillard E Kesari S Maire CL Golebiowski D Harrington EP Alberta JA Kane MF Theisen M Ligon KL Rowitch DH Stiles CD The central nervous system-restricted transcription factor Olig2 opposes p53 responses to genotoxic damage in neural progenitors and malignant glioma Cancer Cell 2011 19 359 371 21397859
12 Kosty J Lu F Kupp R Mehta S Lu QR Harnessing OLIG2 function in tumorigenicity and plasticity to target malignant gliomas Cell Cycle 2017 16 1654 1660 28806136
13 Parmar MK Torri V Stewart L Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints Stat Med 1998 17 2815 2834 9921604
14 Higgins JP Thompson SG Deeks JJ Altman DG Measuring inconsistency in meta-analyses BMJ 2003 327 557 560 12958120
15 Batista K Costa B Pablo I Vega IF Morales J Alvarez AV Meilán A Astudillo A Alvarez KY Analysis of Olig2 and YKL-40 expression: a clinicopathological/immunohistochemical study for the distinction between subventricular zone II and III glioblastomas Folia Neuropathol 2016 54 31 39 27179219
16 Schäfer S Behling F Skardelly M Koch M Ott I Paulsen F Tabatabai G Schittenhelm J Low FoxG1 and high Olig-2 labelling indices define a prognostically favourable subset in isocitrate dehydrogenase (IDH)-mutant gliomas Neuropathol Appl Neurobiol 2018 44 207 223 29053887
17 Behling F Barrantes-Freer A Behnes CL Stockhammer F Rohde V Adel-Horowski A Rodríguez-Villagra OA Barboza MA Brück W Lehmann U Stadelmann C Hartmann C Expression of Olig2, Nestin, NogoA and AQP4 have no impact on overall survival in IDH-wildtype glioblastoma PLoS One 2020 15 e0229274 32160197
18 Zhong Y Cai HQ Ma C Zhang MJ He J Wang MR Wan HJ Significance of Olig2 expression in glioblastoma [J] Zhongguo Weiqinxi Shenjing Waike Zazhi 2020 25 5
19 Zhou J Shi LF Wang Z Li M Zhang JS Mao Y Hua W OLIG2 expression level could be used as an independent prognostic factor for patients with cerebellar Glioblastoma (cGBM) Clinics (Sao Paulo) 2023 78 100120 37001387
20 Mei N Lu Y Yang S Jiang S Ruan Z Wang D Liu X Ying Y Li X Yin B Oligodendrocyte Transcription Factor 2 as a Potential Prognostic Biomarker of Glioblastoma: Kaplan-Meier Analysis and the Development of a Binary Predictive Model Based on Visually Accessible Rembrandt Image and Magnetic Resonance Imaging Radiomic Features J Comput Assist Tomogr 2023 47 650 658 37380154
21 Ahmed R Oborski MJ Hwang M Lieberman FS Mountz JM Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods Cancer Manag Res 2014 6 149 170 24711712
22 Kong BH Moon JH Huh YM Shim JK Lee JH Kim EH Chang JH Kim DS Hong YK Kim SH Lee SJ Kang SG Prognostic value of glioma cancer stem cell isolation in survival of primary glioblastoma patients Stem Cells Int 2014 2014 838950 25580136
23 Liang J Piao Y Holmes L Fuller GN Henry V Tiao N de Groot JF Neutrophils promote the malignant glioma phenotype through S100A4 Clin Cancer Res 2014 20 187 198 24240114
24 Bambury RM Teo MY Power DG Yusuf A Murray S Battley JE Drake C O'Dea P Bermingham N Keohane C Grossman SA Moylan EJ O'Reilly S The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme J Neurooncol 2013 114 149 154 23780645
25 Hashimoto K Nishimura S Shinyashiki Y Ito T Akagi M Characterizing inflammatory markers in highly aggressive soft tissue sarcomas Medicine (Baltimore) 2022 101 e30688 36181081
26 Rahbar A Cederarv M Wolmer-Solberg N Tammik C Stragliotto G Peredo I Fornara O Xu X Dzabic M Taher C Skarman P Söderberg-Nauclér C Enhanced neutrophil activity is associated with shorter time to tumor progression in glioblastoma patients Oncoimmunology 2016 5 e1075693 27057448
27 Suzuki A Nobusawa S Natsume A Suzuki H Kim YH Yokoo H Nagaishi M Ikota H Nakazawa T Wakabayashi T Ohgaki H Nakazato Y Olig2 labeling index is correlated with histological and molecular classifications in low-grade diffuse gliomas J Neurooncol 2014 120 283 291 25085214
28 Lu F Chen Y Zhao C Wang H He D Xu L Wang J He X Deng Y Lu EE Liu X Verma R Bu H Drissi R Fouladi M Stemmer-Rachamimov AO Burns D Xin M Rubin JB Bahassi EM Canoll P Holland EC Lu QR Olig2-Dependent Reciprocal Shift in PDGF and EGF Receptor Signaling Regulates Tumor Phenotype and Mitotic Growth in Malignant Glioma Cancer Cell 2016 29 669 683 27165742
29 Szu JI Tsigelny IF Wojcinski A Kesari S Biological functions of the Olig gene family in brain cancer and therapeutic targeting Front Neurosci 2023 17 1129434 37274223
30 Suvà ML Rheinbay E Gillespie SM Patel AP Wakimoto H Rabkin SD Riggi N Chi AS Cahill DP Nahed BV Curry WT Martuza RL Rivera MN Rossetti N Kasif S Beik S Kadri S Tirosh I Wortman I Shalek AK Rozenblatt-Rosen O Regev A Louis DN Bernstein BE Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells Cell 2014 157 580 594 24726434
31 Durand KS Guillaudeau A Weinbreck N DeArmas R Robert S Chaunavel A Pommepuy I Bourthoumieu S Caire F Sturtz FG Labrousse FJ 1p19q LOH patterns and expression of p53 and Olig2 in gliomas: relation with histological types and prognosis Mod Pathol 2010 23 619 628 20081802
32 Mo H Magaki S Deisch JK Raghavan R Isocitrate Dehydrogenase Mutations Are Associated with Different Expression and DNA Methylation Patterns of OLIG2 in Adult Gliomas J Neuropathol Exp Neurol 2022 81 707 716 35856894
33 Wang ZH The study of predicting the expression level of cancer stem cell marker genes in lower-grade gliomas based on MRI radiomic features. PhD Thesis. Nanchang University
34 Chen YS Guo Y Shen HW Zhang P Chen H [Screening function enrichment and related signaling pathways bioinformatics analysis of differentially expressed gene in glioma] Zhonghua YiXue ZaZhi 2019 99 2311 2314 31434409
35 McGirt MJ Chaichana KL Attenello FJ Weingart JD Than K Burger PC Olivi A Brem H Quinoñes-Hinojosa A Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas Neurosurgery 2008 63 700 707; author reply 707 18981880
36 Tabu K Ohba Y Suzuki T Makino Y Kimura T Ohnishi A Sakai M Watanabe T Tanaka S Sawa H Oligodendrocyte lineage transcription factor 2 inhibits the motility of a human glial tumor cell line by activating RhoA Mol Cancer Res 2007 5 1099 1109 17951409
37 Van Meir EG Hadjipanayis CG Norden AD Shu HK Wen PY Olson JJ Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma CA Cancer J Clin 2010 60 166 193 20445000
